News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: SYNBIOTIC SE (von NuWays AG): BUY
NuWays AG releases research on the classification of SYNBIOTIC SE, updating to a BUY recommendation with a target price of EUR 12.40. The group's performance is driven by strong results from WEECO Pharma and recent acquisitions -
-
-
COMMUNIQUÉ DE PRESSE
SYNBIOTIC integrates greensby: Universal platform for the entire hemp and cannabis industry
SYNBIOTIC integrates greensby with the acquisition of 50.2% shares, creating a universal platform for the hemp and cannabis industry. greensby connects patients, pharmacies, telemedicine providers, and consumers, offering up to 4,000 products -
